In mouse models, CD8+ T-cells and IFNγ were required for development of HLH45 and an anti-IFNγ antibody was approved by the FDA to treat HLH resistant to conventional treatments.51 The gene discussed is IFNG; the disease is hemophagocytic syndrome.